[go: up one dir, main page]

MX2016015389A - Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. - Google Patents

Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.

Info

Publication number
MX2016015389A
MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A
Authority
MX
Mexico
Prior art keywords
human
cynomolgus
antibody
epsilon
cells
Prior art date
Application number
MX2016015389A
Other languages
English (en)
Inventor
Lifke Valeria
Offner Sonja
Moessner Ekkehard
Jaeger Christiane
Ritter Mirko
Platzer Josef
Tiefenthaler Georg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015389A publication Critical patent/MX2016015389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un aspecto como se reporta en la presente es el uso de un método que comprende la etapa de inmunizar a un animal experimental tres veces con PBLs primarios de mono cinomolgo, por lo cual los PBLs enriquecen opcionalmente las células T sin utilizar PBLs humanos primarios como inmuógeno y sin utilizar un agente desnaturalizante para producir un anticuerpo de reacción cruzada humano-cinomolgo que se enlaza específicamente al CD3 épsilon humano de la SEQ ID NO: 02 y se enlaza específicamente a un polipéptido de la SEQ ID NO: 01, en donde el anticuerpo de reacción cruzada humano-cinomolgo se enlaza específicamente a las células T humanas y de mono cinomolgo, activa las células T humanas y no se enlaza al mismo epítopo que el anticuerpo OKT3, el anticuerpo UCHT1 y/o el anticuerpo SP34.
MX2016015389A 2014-05-28 2015-05-22 Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. MX2016015389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170140 2014-05-28
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
MX2016015389A true MX2016015389A (es) 2017-04-13

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015389A MX2016015389A (es) 2014-05-28 2015-05-22 Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.

Country Status (13)

Country Link
US (3) US20170233475A1 (es)
EP (2) EP3149041A1 (es)
JP (1) JP6738285B2 (es)
KR (1) KR20170003591A (es)
CN (1) CN106459201A (es)
AU (1) AU2015266077A1 (es)
BR (1) BR112016022819A2 (es)
CA (1) CA2942453A1 (es)
IL (1) IL247740A0 (es)
MX (1) MX2016015389A (es)
RU (1) RU2016151235A (es)
SG (1) SG11201609950YA (es)
WO (1) WO2015181098A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3048174A1 (en) * 2016-12-22 2018-06-28 Daiichi Sankyo Company, Limited Anti-cd3 antibody and molecules comprising the antibody
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
MX2019014274A (es) 2017-06-02 2020-01-23 Hoffmann La Roche Metodo de tratamiento.
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3634998B8 (en) 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
AU2018290228B2 (en) 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
MX2020003087A (es) * 2017-09-21 2020-08-17 Wuxi Biologics Ireland Ltd Anticuerpos anti-cd3epsilon novedosos.
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
JP7166342B2 (ja) * 2017-11-30 2022-11-07 エフ．ホフマン－ラ ロシュ アーゲー Ｂ細胞培養法
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
DK3802608T3 (da) * 2018-05-24 2025-06-10 Janssen Biotech Inc Anti-cd3-antistoffer og anvendelser deraf
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
BR112022023978A2 (pt) * 2020-05-27 2023-02-07 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno cd3 e usos dos mesmos
AU2021350342A1 (en) * 2020-09-24 2023-03-09 Morphosys Ag Novel human antibodies binding to human CD3 epsilon
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
US12258406B2 (en) 2021-03-24 2025-03-25 Twist Bioscience Corporation Antibodies that bind CD3 Epsilon
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
US20250206819A1 (en) * 2022-03-22 2025-06-26 Morphosys Ag Deimmunized antibodies specific for cd3
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP7701982B2 (ja) 2022-04-13 2025-07-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の薬学的組成物及び使用方法
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
SG10201606980VA (en) * 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
JP2010524435A (ja) * 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的二重特異性バインダー
CN103842383B (zh) * 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
HRP20190756T1 (hr) * 2011-05-21 2019-06-14 Macrogenics, Inc. Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3
EP3143045A1 (en) * 2014-05-12 2017-03-22 Numab AG Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
US20200299385A1 (en) 2020-09-24
US20170233475A1 (en) 2017-08-17
JP6738285B2 (ja) 2020-08-12
IL247740A0 (en) 2016-11-30
RU2016151235A3 (es) 2019-01-18
SG11201609950YA (en) 2016-12-29
JP2017516786A (ja) 2017-06-22
CA2942453A1 (en) 2015-12-03
KR20170003591A (ko) 2017-01-09
BR112016022819A2 (pt) 2018-01-16
EP3763739A1 (en) 2021-01-13
CN106459201A (zh) 2017-02-22
RU2016151235A (ru) 2018-06-28
AU2015266077A1 (en) 2016-09-29
WO2015181098A1 (en) 2015-12-03
US20200325224A1 (en) 2020-10-15
EP3149041A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
IL317134A (en) An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ714516A (en) Human antibodies to clostridium difficile toxins
MX2022007774A (es) Anticuerpos de union a abril modificados.
NZ607969A (en) Cd33 binding agents
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2020007021A (es) Receptor quimerico de antigeno anti-cd19 humanizado.
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
JP2017516786A5 (es)
AR091605A1 (es) Proteinas de union anti-mesotelina
MX384246B (es) POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.
WO2013064700A3 (en) Chimeric human-camel antigens and their use